Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

Popular GLP-1 weight loss drugs like Ozempic and Zepbound may help lower a woman’s risk for 14 types of cancer, a new study suggests.Researchers compared GLP-1 ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

Findings for matched groups of patients with obesity and diabetes taking first-generation GLP-1 RA or undergoing bariatric metabolic surgery. (HealthDay News) — Glucagon-like peptide-1 receptor ...

Newer generation, highly potent GLP-1 drugs like Ozempic and Zepbound might even convey a greater advantage in reducing cancer risk, but they weren’t studied in this report, researchers said.

The drugs had a 41% lower risk of cancers compared with weight-loss surgery Results indicate the drugs lower risk of cancer beyond the benefits of weight loss MONDAY, May 19, 2025 (HealthDay News) — ...